SDSemaglutide Dosage

Editorial Policy

How we research, review, update, and separate editorial from advertising.

Sourcing

Every dosage claim on this site is sourced to one of the following, in order of priority:

  1. Current FDA-approved prescribing information for the specific product.
  2. Novo Nordisk medication guide or patient information leaflet.
  3. Peer-reviewed publications of pivotal clinical trials (STEP, SUSTAIN, PIONEER, STEP UP, SELECT).
  4. Professional society guidance (ADA, Endocrine Society, AACE).

Secondary sources (news articles, forum posts, AI-generated content) are not used as the basis for any dosage claim.

Review cadence

  • New content is reviewed by our medical reviewer before publication.
  • All dosage content is re-reviewed at least every six months.
  • Critical updates (e.g., a new FDA label revision, a safety communication) trigger an immediate review of affected pages.
  • Reader-reported errors are acknowledged within 24 hours for medical content.

Corrections policy

Factual errors are corrected in place, with a dated "Last reviewed" note on the affected page. Material corrections — not typos or minor edits — are noted in the page footer with a brief description of what changed.

Editorial independence

Semaglutide Dosage is ad-supported. We accept display advertising via Google AdSense and direct advertisers. Advertising relationships are separated from editorial operations by policy and practice:

  • Advertisers cannot commission, edit, or remove articles.
  • Advertisers cannot place content that impersonates editorial ("native" ads). Paid placements are labeled "Advertisement".
  • Tool calculations are unaffected by advertiser relationships.
  • We do not take commissions on drug sales, telehealth referrals, or prescriptions.

AI disclosure

We use AI tools to assist with drafting and copy-editing, but every page is reviewed by a human editor and a licensed pharmacist before publication. No dosage content is published based solely on AI output.

Author and reviewer identification

Bylines appear on every substantive article. Medical reviewer identity and credentials are published on our medical reviewer page.

Conflicts of interest

Our team members disclose any financial relationships with pharmaceutical companies, telehealth services, or compounding pharmacies relevant to semaglutide. As of publication, no team member has such relationships.

Questions

Editorial questions: contact@semaglutidedosage.com.